S*Bio presents positive safety and tolerability results for its oral JAK2 inhibitor SB1518 for the treatment of myelofibrosis

15-Jun-2010 - Singapore

S*BIO Pte Ltd announced the presentation of positive safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) results for its novel oral JAK2 inhibitor, SB1518, at the 15th Congress of the European hematology Association (EHA), June 10-13, in Barcelona, Spain.

Data was presented on the Phase 1 clinical results of the Phase 1/2 dose-escalation trial of SB1518 from 20 patients treated at multiple dose levels ranging between 100 mg to 600 mg once daily. Clinical improvements were observed in hemoglobin, platelet and splenomegaly categories. The dose-limiting toxicities were gastrointestinal related and were only seen at the 600 mg dose level. The study was conducted at three sites in Australia - Peter MacCallum Cancer Center, Royal Melbourne Hospital, and Royal Adelaide Hospital.

“The clinical findings demonstrate SB1518’s potential as a viable treatment for myelofibrosis,” said Dr. Jan-Anders Karlsson, CEO of S*BIO. “These results are consistent with the data presented at the ASH Annual Meeting in 2009 from our U.S. Phase 1 trials in which safety, tolerability and signs of activity in different disease states had been observed. The positive findings allowed us to advance rapidly our clinical program and complete enrollment of the Phase 2 myelofibrosis trials for SB1518 to test further the safety and efficacy of our compound.”

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances